Clinical trial · Observational
An Observational Study of Patients With Malignant Lymphomas Treated With MabThera® SC in Everyday Clinical Practice
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
This observational study aims to assess the therapeutic responsiveness of MabThera SC in patients with malignant lymphomas under everyday clinical practice conditions. Patients with previously untreated CD-20 positive follicular non-Hodgkin's lymphoma (NHL) or previously untreated CD-20 positive diffuse large B-cell lymphoma (DLBCL) who are planned for therapy with MabThera SC according to the assessment of the physician will be prospectively enrolled for observation. No study specific measures are required; treatment and documentation will be performed according to usual clinical practice.
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Lymphoma, B-Cell, Lymphoma, Follicular | Lymphoma | ONTOLOGY_EXACT | 0.85 |
Interventions
Interventions (0)
Data not yet available
Design
Arms and outcomes
Arms (2)
- label
- Follicular NHL Cohort
- label
- DLBCL Cohort
Primary outcomes (1)
- measure
- Proportion of patients in both indications (DLBCL and follicular NHL) who have reached a complete remission (CR), including unconfirmed complete remission (CRu)
- timeFrame
- Up to 2 years
Secondary outcomes (3)
- measure
- Total response rate
- timeFrame
- Up to 2.5 years
- measure
- Two-year progression-free survival rate for patients with follicular lymphoma under maintenance therapy
- timeFrame
- 2 years
Eligibility
Eligibility (as posted)
- Sex
- All
- Minimum age
- 18 Years
Show eligibility criteria text
Inclusion Criteria: * Women and men aged \>=18 years * Previously untreated CD-20 positive follicular NHL * Previously untreated CD-20 positive DLBCL * Planned therapy with MabThera SC according to the assessment of the physician (before the start and independent from this study) * Suitability for the therapy with MabThera SC Exclusion Criteria: All contraindications, interactions and incompatibilities for therapy with MabThera SC
References
Publications (0)
Data not yet available